Paul Stoffels, incoming Galapagos CEO (Michael Kovac/Getty Images)
January 26, 2022 04:51 PM ESTUpdated January 27, 08:24 AM
People

Big Phar­ma R&D leg­end Paul Stof­fels is trad­ing his J&J ti­tle for the CEO role at one of the most deeply trou­bled biotechs in the in­dus­try

John Carroll

Editor & Founder

Af­ter 20 years work­ing at the pin­na­cle of Big Phar­ma R&D, tak­ing lead roles in J&J’s pipeline re­vamp and a quick­ly de­vel­oped, one-shot Covid vac­cine …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times